'It Totally Backfired' - The Pitfalls of Alzheimer's Genetic Testing - Reuters

27/6/23, 23:47 'It totally backfired': The pitfalls of Alzheimer's genetic testing | Reuters
Learn more about
Future of Health
'It totally backfired': The pitfalls of Alzheimer's genetic testing

By Julie Steenhuysen
April 22, 2023 8:21 AM GMT-3 · Updated 2 months ago
Feedback
https://www.reuters.com/business/healthcare-pharmaceuticals/it-totally-backfired-pitfalls-alzheimers-genetic-testing-2023-04-21/?utm_medium=Social&utm_source=twitter 1/20

CHICAGO, April 21 (Reuters) - Wendy Nelson watched her mother slowly die of Alzheimer's disease, unable to move or swallow at the end. "All her pleasures of life
were gone," Nelson said.
Grief-stricken, terrified of facing the same death, Nelson ordered 23andMe(ME.O) DNA test kits for Christmas 2020 for herself and three adult daughters.
A Boston-based biotech executive who is now 52, Nelson hoped the kits would provide reassurance. They delivered the worst possible result. Nelson has two copies of
the APOE4 gene variant that increases the risk of Alzheimer's, which means her risk of developing the disease is eight to 12 times higher than people with the most
common version of APOE.
"It totally backfired," she said.
Millions of Americans are expected to test for Alzheimer's in the coming years – some like Nelson, with at-home test kits, others at labs, as new drugs for people with
early Alzheimer's from partners Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) and Eli Lilly and Co (LLY.N) usher in sweeping change in approaches to treatment of the
disease.
Testing for the APOE4 gene variant among Americans being treated for Alzheimer's has more than doubled from a year ago, an exclusive analysis of medical records
for Reuters by health data firm Truveta found. The increase was driven by the new treatments that promise to slow the progression of the disease, but also carry risks,
especially for people like Nelson carrying two copies of APOE4.
Feedback
Advertisement · Scroll to continue
My View Following Saved
Yet few support services are available to help people deal with the implications of APOE4 testing, according to interviews with more than a dozen neurologists and
genetic counselors. Alzheimer's patients and caregivers face a shortage of genetic counselors to explain the tests and help them navigate the psychological, medical,
financial and legal consequences.
Eisai and Biogen's Leqembi, which arrived on the market in January, costs $26,500 a year and is not covered by Medicare outside of clinical trials. Medicare has said it
will expand coverage if the drug is granted full U.S. approval, expected this summer.
"When you learn that information, you're potentially learning information about your siblings, about your children," said Emily Largent, a bioethicist and health policy
expert at the University of Pennsylvania Perelman School of Medicine.
Feedback
"People describe feeling existential dread."
As a scientist, Nelson understood intellectually what her APOE4 results meant, but they created emotional havoc for her family.
She had inherited one copy of APOE4 from her mother and the other from her father, who was showing no symptoms of Alzheimer's at the time.
When her father's memory began to fail a year later, one of her two sisters doubted it could be Alzheimer's, Nelson said. Nelson knew he had to have the disease,
because of her genetic test results.
The tests also showed that each of Nelson's three adult daughters had one copy of APOE4, which triples or quadruples the risk of developing the disease - confronting
them with their own Alzheimer's risks along with their mother's.
Nelson's daughter, Lindsey, 22, and a fourth year nursing student at New York University, said she was traumatized when, even before testing, Nelson talked about
exploring assisted suicide rather than suffer her mother’s fate.
"I would yell at her, cover my ears and run away," Lindsey said. "There are many complicated emotions involved."
Nelson's eldest daughter, Lexi, 24, who works in data analytics, turned to research showing that lifestyle changes such as weight lifting can improve cognitive function.
"I've tried really hard to improve my sleep, I’m exercising a lot," she said.
Feedback
Her youngest, Pam, 20, a sophomore biology major at UCLA, said she takes comfort in knowing that her mother's result is not a diagnosis. "It's just a risk factor, and
there are many other factors that influence what will happen."
Leqembi is not suitable for Nelson, who is not symptomatic. Even if she were eligible, she said she is not a fan because of the risk of brain swelling, which is higher for
people with two copies of APOE4.
Nelson is pinning her hopes on an experimental pill from Alzheon Inc, which is being tested in people with early Alzheimer's who have two copies of APOE4.
Feedback
[1/10] Lexi Nelson talks to her mother Wendy about her income tax filing at their home in Foxborough, Massachusetts, U.S., March 21,
2023. Wendy Nelson's mother died from Alzheimer's disease, her father... Read more
She is working her way through a bucket list of trips. In February, she climbed Mt. Kilimanjaro to raise money for a cancer charity, and she would like to visit Patagonia,
the Greek Islands, South Africa, possibly Antarctica.
If treatment fails, she said she has her "exit plan": legal euthanasia through a clinic in Switzerland. "I do not want to live the way my mom had to live her last five years
of life. She was miserable," she said.
THE TESTING REVOLUTION
Until recently, most doctors tended not to order genetic tests to determine Alzheimer's risk, because there were no effective treatments to slow or prevent the disease.
That changed with Leqembi, which was shown to reduce the rate of cognitive decline by 27% in patients with mild Alzheimer's. Eli Lilly's donanemab is in clinical trials
with results expected by June.
Both drugs remove the buildup in the brain of amyloid plaques associated with Alzheimer's, and are viewed as a first step towards even more effective treatments.
Both can cause swelling and microbleeds in the brain. US regulators recommend genetic testing before starting treatment with Leqembi.
Feedback
"With this drug, it behooves us to check," said Dr. Sarah Kremen, a neurologist at Cedars-Sinai in Los Angeles.
In the four months ahead of U.S. approval of Leqembi in January, APOE4 testing among people over 55 who visited a doctor within the last 30 days increased 125%.
From September 2022 to January 2023, the rate averaged 1.4 tests per 100,000 patients, compared with 0.6 tests per 100,000 patients in the same period a year
earlier, the analysis by Seattle-based Truveta found.
The analysis was based on a review of medical records from 7.9 million adults at 28 major U.S. hospital systems. It does not include at-home consumer tests.
The National Institutes of Health estimates up to 25% of people in the United States have one copy of APOE4 and up to 5% have two copies.
Yet there is a shortage of genetic counselors to help families deal with the implications of having two copies of APOE4.
A 2018 study in the European Journal of Human Genetics found the U.S. had just one trained genetic counselor per 82,000 people. The United Kingdom had 1 per
193,500.
Banner Alzheimer's Institute in Phoenix, which is testing Lilly's donanemab, is researching an interactive online platform to deliver APOE results to volunteers being
screened for enrollment in the trial.
"We needed a scalable way to warn people about the potential benefits and risks of genetic disclosure," said Dr. Eric Reiman, Banner's director.
While the U.S. Genetic Information Nondiscrimination Act (GINA) bans discrimination in employment and health insurance, it does not cover long-term care and
Feedback
disability and life insurance.
Some members of families with increased genetic risk of Alzheimer's say it might be better not to know at all.
Dovie Bryant, 77, who is taking part in the Lilly trial, lost her mother to Alzheimer's in 2012.
When she shared with her five siblings that she had one copy of the APOE4 variant, none wanted to find out their own status.
Her brother Jim Painter, 71, said he feared testing could make it harder to pass a health screening to move into a retirement community that offers increasing levels of
care as a person ages.
"That might be a red flag," Painter said.
Reporting by Julie Steenhuysen; editing by Caroline Humer and Suzanne Goldenberg
Our Standards: The Thomson Reuters Trust Principles.
Read Next
Future of Health
Exclusive: Rotavirus childhood vaccine shortage hits four African countries
August 11, 2022
Future of Health
Climate change puts Lyme disease in focus for France's Valneva after COVID blow
Feedback
August 8, 2022
Future of Health
U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug
August 5, 2022
Future of Health
CanSinoBIO's inhaled COVID booster stronger against BA.1 Omicron subvariant than Sinovac shot
July 29, 2022
Newsletter | Twice a week.
Reuters Health Rounds

Keep up with the latest medical breakthroughs, healthcare trends, pharmaceutical news and more.
Sign up
More from Reuters

Aston Martin ties up with Lucid on EV tech Aston Martin ties up
(1:30) - June 26, 2023
Watch more videos with Lucid on EV
tech
01:30
Honda recalls 1.3

million vehicles
worldwide
00:35
Business Lookahead:
The only way is up
01:35
Fed may hike rates

more than predicted
-CIO
Feedback
01:33
US stock market is
like 'two markets' -
CIO
Sponsored Content
Oil. What next? Trending news on Gold Markets. The latest news on commodity
Sponsored by MarketViews Sponsored by MarketViews markets from leading experts
Sponsored by MarketViews
The latest trends on responsible Discover the latest trends and ideas What is the latest on ETFs?
investing for retirement planning. Sponsored by MarketViews
Sponsored by MarketViews Sponsored by MarketViews
Business
Feedback
KPMG to cut 5% of US jobs in fresh round of layoffs

World at Work · June 26, 2023
KPMG is laying off 5% of its U.S. employees after feeling the pinch of "economic headwinds,
coupled with historically low attrition," a spokesperson for the Big Four accounting giant said on
Monday.
Litigation
J&J's $8.9 billion talc settlement faces US bankruptcy test
1:20 PM GMT-3
Finance
Bank of America to expand in four US states, closing gap with JPMorgan
10:28 AM GMT-3
ADAS, AV & Safety

Audi ex-boss becomes first VW board member sentenced over diesel scandal
9:51 AM GMT-3
Feedback
Future of Money
Cryptoverse: Bitcoin bounces on BlackRock buzz
3:16 PM GMT-3
Sponsored Content
Discover the latest trends and ideas Oil. What next? The latest news on commodity
for retirement planning. Sponsored by MarketViews markets from leading experts
Robotics and Artificial Intelligence. What is the latest on ETFs? The latest trends on responsible
Discover the trends. Sponsored by MarketViews investing
Sponsored Content
The Latest Market Thinking From The World's Trending news on Gold Markets. Discover the latest trends and ideas for
Finance Experts Sponsored by MarketViews retirement planning.
Oil. What next? The latest news on commodity markets from Robotics and Artificial Intelligence. Discover the
Sponsored by MarketViews leading experts trends.
Latest Browse
Home World
Feedback
Business
Media Legal
Videos Markets
Pictures Breakingviews
Technology
Graphics
Investigations
Lifestyle
About Reuters
About Reuters
Careers
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App

Newsletters
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching
billions of people worldwide every day. Reuters provides business, financial, national and international news to
professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Westlaw Onesource Checkpoint

Build the strongest argument relying on authoritative content, The most comprehensive solution to manage all your complex and The industry leader for online information for tax, accounting and
attorney-editor expertise, and industry defining technology. ever-expanding tax and compliance needs. finance professionals.
Feedback
Refinitiv Products
Refinitiv Workspace Refinitiv Data Catalogue Refinitiv World-Check

Access unmatched financial data, news and content in a highly- Browse an unrivalled portfolio of real-time and historical market data Screen for heightened risk individual and entities globally to help
customised workflow experience on desktop, web and mobile. and insights from worldwide sources and experts. uncover hidden risks in business relationships and human networks.
Advertise With Us Advertising Guidelines Coupons
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
Cookies Terms of Use Privacy Digital Accessibility Corrections Site Feedback
© 2023 Reuters. All rights reserved
Feedback

'It Totally Backfired' - The Pitfalls of Alzheimer's Genetic Testing - Reuters

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

'It Totally Backfired' - The Pitfalls of Alzheimer's Genetic Testing - Reuters

Uploaded by

Copyright:

Available Formats

27/6/23, 23:47 'It totally backfired': The pitfalls of Alzheimer's genetic testing | Reuters

Learn more about

'It totally backfired': The pitfalls of Alzheimer's genetic testing

"It totally backfired," she said.

My View Following Saved

Advertisement · Scroll to continue

Advertisement · Scroll to continue

THE TESTING REVOLUTION

Advertisement · Scroll to continue

"That might be a red flag," Painter said.

Reporting by Julie Steenhuysen; editing by Caroline Humer and Suzanne Goldenberg

Our Standards: The Thomson Reuters Trust Principles.

Newsletter | Twice a week.

Reuters Health Rounds

More from Reuters

Honda recalls 1.3

Fed may hike rates

KPMG to cut 5% of US jobs in fresh round of layoffs

ADAS, AV & Safety

Download the App

Information you can trust

Thomson Reuters Products

Westlaw Onesource Checkpoint

Refinitiv Workspace Refinitiv Data Catalogue Refinitiv World-Check

Advertise With Us Advertising Guidelines Coupons

Cookies Terms of Use Privacy Digital Accessibility Corrections Site Feedback

© 2023 Reuters. All rights reserved

You might also like